NEW YORK (GenomeWeb News) – Bio-Reference Laboratories today said that revenues for its fiscal fourth quarter climbed 18 percent year over year, in spite of a reduction in reimbursements.

For the three months ended Oct. 31, Bio-Reference posted $192.2 million in revenues, compared to $163.5 million a year ago, and edging out the consensus Wall Street estimate of $192.0 million.

The clinical laboratory said that revenue per patient inched up to $80.80 from $79.66, while the number of patients served increased to 2,350 from 2,039.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.